Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$153.41 USD

153.41
3,229,121

-3.19 (-2.04%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $153.70 +0.29 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should Value Investors Buy Cardinal Health (CAH) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Reasons to Hold Patterson Companies (PDCO) in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

Zacks Equity Research

Here's Why You Should Hold McKesson (MCK) in Your Portfolio

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Zacks Equity Research

Phibro Stock (PAHC) Rises 7% YTD: Will the Run Continue?

by Zacks Equity Research

Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.

Zacks Equity Research

3 Reasons Growth Investors Will Love Cardinal (CAH)

by Zacks Equity Research

Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

Zacks Equity Research

GE HealthCare (GEHC) Renews HealthCare Alliance With Hartford

by Zacks Equity Research

GE HealthCare (GEHC) and Hartford Healthcare announce the renewal of The Care Alliance. The renewal will extend the collaboration through 2030, which started back in 2016.

Zacks Equity Research

UnitedHealth (UNH) Faces Investigation Following Cyberattack

by Zacks Equity Research

A cyberattack on UnitedHealth's (UNH) subsidiary, Change Healthcare, last month continues to impact its healthcare services. The HHS investigation will determine any breach of protected health data.

Zacks Equity Research

Reasons to Add Stryker (SYK) Stock in Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Zacks Equity Research

Revvity's (RVTY) New Launch to Boost Research Productivity

by Zacks Equity Research

Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.

Zacks Equity Research

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).

Zacks Equity Research

Walgreens' (WBA) AllianceRx Pharmacy Will Distribute VIVJOA

by Zacks Equity Research

Walgreens' (WBA) specialty pharmacy patients now have exclusive access to 240+ limited distribution drugs.

Zacks Equity Research

HealthEquity (HQY) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the fourth quarter of fiscal 2024.

Zacks Equity Research

Here's Why You Should Hold Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Zacks Equity Research

Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System

by Zacks Equity Research

Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.

Zacks Equity Research

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Accuray's (ARAY) solid product demand raises optimism about the stock.

Zacks Equity Research

Here's Why Cardinal Health (CAH) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's Why Investors Should Buy Phibro (PAHC) Stock Now

by Zacks Equity Research

Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.

Zacks Equity Research

Align Technology (ALGN) Gains From Innovation, Macro Issues Ail

by Zacks Equity Research

In terms of innovation, Align Technology successfully launched its first subscription-based clear aligner program Doctor Subscription Program (DSP) worldwide.

Zacks Equity Research

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.

Zacks Equity Research

Edwards Lifesciences (EW) Up 21.8% YTD: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.

Zacks Equity Research

Inspira Technologies (IINN) Strives to Get AMAR Nod for ART100

by Zacks Equity Research

The AMAR submission is a strategic move by Inspira Technologies (IINN), positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART).

Zacks Equity Research

Johnson & Johnson (JNJ), Nvidia Unite to Boost AI for Surgery

by Zacks Equity Research

Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.

Zacks Equity Research

Here's Why You Should Retain HealthEquity (HQY) Stock Now

by Zacks Equity Research

HealthEquity's (HQY) strength in HSAs raises optimism about the stock.

Zacks Equity Research

Cencora (COR) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.